Use of clomiphene citrate alone, urinary follicle-stimulating hormone alone, or both combined sequentially in patients with unexplained subfertility undergoing intrauterine insemination: A randomized trial;

dc.authorscopusid34167470000
dc.authorscopusid35738457600
dc.authorscopusid13008094600
dc.contributor.authorAyaz,R.
dc.contributor.authorAşoglu,M.R.
dc.contributor.authorAyas,S.
dc.date.accessioned2024-05-25T12:32:35Z
dc.date.available2024-05-25T12:32:35Z
dc.date.issued2018
dc.departmentOkan Universityen_US
dc.department-tempAyaz R., University of Health Sciences, Van Traning and Research Hospital, Clinic of Perinatology, Van, Turkey; Aşoglu M.R., University of Maryland Medical Center, Clinic of Obstetrics and Gynecology and Reproductive Sciences, Baltimore, MD, United States; Ayas S., Okan University, Faculty of Medicine, Department of Obstetrics and Gynecology, İstanbul, Turkeyen_US
dc.description.abstractObjective: To compare the successes of clomiphene citrate (CC) alone, pure human urinary follicle-stimulating hormone (uFSH) alone, and both combined sequentially in patients with unexplained subfertility couples undergoing intrauterine insemination (IUI). Materials and Methods: Patients aged 18-38 years who had a normal uterine cavity, at least one normal fallopian tube, and regular menses and were unable to conceive despite unprotected intercourse for at least 12 months were randomized to receive CC alone, uFSH alone, or sequential CC and uFSH before a single IUI. The primary outcomes were clinical pregnancy and live birth rates. The study was approved by the ethics committee of our institution. Results: A total of 135 patients were randomized, and 121 of these were able to complete the study. Of these, 30% (n=36) had CC alone, 34% (n=41) had uFSH alone, and 36% (n=44) had sequential CC and uFSH. The three groups did not significantly differ in terms of age, duration of infertility, hormone levels, and semen parameters. For CC alone, uFSH alone, and sequential CC plus uFSH groups, pregnancy rates were 8.3%, 17.1%, and 18.2%, respectively (p>0.05), and live birth rates were 8.3%, 12.1%, and 13.6%, respectively (p>0.05). Conclusion: In women with unexplained infertility, use of uFSH seemed to increase the success rate compared with CC alone. The sequential regime can significantly reduce the treatment cost if gonadotropin/IUI cycles are planned. © 2018 by Turkish Society of Obstetrics and Gynecology.en_US
dc.identifier.citationcount3
dc.identifier.doi10.4274/TJOD.99835
dc.identifier.endpage248en_US
dc.identifier.issn2149-9330
dc.identifier.issue4en_US
dc.identifier.scopus2-s2.0-85072814688
dc.identifier.scopusqualityQ3
dc.identifier.startpage243en_US
dc.identifier.urihttps://doi.org/10.4274/TJOD.99835
dc.identifier.urihttps://hdl.handle.net/20.500.14517/2400
dc.identifier.volume15en_US
dc.language.isoen
dc.relation.ispartofTurkish Journal of Obstetrics and Gynecologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.scopus.citedbyCount3
dc.subjectClomiphene citrateen_US
dc.subjectIntrauterine inseminatonen_US
dc.subjectUnexplained subfertilityen_US
dc.subjectUrinary follicle-stimulating hormoneen_US
dc.titleUse of clomiphene citrate alone, urinary follicle-stimulating hormone alone, or both combined sequentially in patients with unexplained subfertility undergoing intrauterine insemination: A randomized trial;en_US
dc.title.alternativeSadece klomifen sitrat, sadece üriner folikül stimülan hormon ve her ikisinin kombinasyonu ile intrauterin aşılama yapılan açıklanamayan infertilitesi olan hastalarda kullanımı: Randomize çalışmaen_US
dc.typeArticleen_US
dspace.entity.typePublication

Files